Scinai Immunotherapeutics (SCNI) Cash & Equivalents (2016 - 2025)

Scinai Immunotherapeutics has disclosed Cash & Equivalents across 10 years of filings, most recently posting $2.0 billion for Q4 2025.

• Cash & Equivalents for Q4 2025 came in at $2.0 billion, up 103362.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 billion (up 103362.32% YoY), and the FY2025 annual result was $2.0 billion, up 103362.32% from the prior year.
• Cash & Equivalents came in at $2.0 billion for Q4 2025 at Scinai Immunotherapeutics, up from $989000.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $48.6 billion in Q1 2021 to a low of $989000.0 in Q2 2025.
• The 5-year median for Cash & Equivalents is $7.9 million (2022), against an average of $2.8 billion.
• Across the five-year window, Cash & Equivalents jumped 114285278.19% in 2021 and sank 99.97% in 2022, its largest moves.
• Scinai Immunotherapeutics' Cash & Equivalents stood at $17.4 million in 2021, then retreated by 18.99% to $14.1 million in 2022, then sank by 65.4% to $4.9 million in 2023, then tumbled by 59.67% to $2.0 million in 2024, then soared by 103362.32% to $2.0 billion in 2025.
• The last three Cash & Equivalents figures came in at $2.0 billion (Q4 2025), $989000.0 (Q2 2025), and $2.0 million (Q4 2024), per Business Quant data.